A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis

por Allanore, Yannick, Wung, Peter, Soubrane, Christina, Esperet, Corinne, Marrache, Frederic, Bejuit, Raphael, Lahmar, Amel, Khanna, Dinesh, Denton, Christopher P
Publicado 2020

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

por Lescure, François-Xavier, Honda, Hitoshi, Fowler, Robert A, Lazar, Jennifer Sloane, Shi, Genming, Wung, Peter, Patel, Naimish, Hagino, Owen
Publicado 2021

Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2

por Kiltz, Uta, Kishimoto, Mitsumasa, Walsh, Jessica A., Sampaio-Barros, Percival, Mittal, Manish, Saffore, Christopher D., Wung, Peter, Ganz, Fabiana, Biljan, Ana, Poddubnyy, Denis
Publicado 2023

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study

por Baraliakos, Xenofon, van der Heijde, Désirée, Sieper, Joachim, Inman, Robert D., Kameda, Hideto, Li, Yihan, Bu, Xianwei, Shmagel, Anna, Wung, Peter, Song, In-Ho, Deodhar, Atul
Publicado 2023

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study

por McInnes, Iain B., Kato, Koji, Magrey, Marina, Merola, Joseph F., Kishimoto, Mitsumasa, Haaland, Derek, Chen, Liang, Duan, Yuanyuan, Liu, Jianzhong, Lippe, Ralph, Wung, Peter
Publicado 2022

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial

por van der Heijde, Désirée, Baraliakos, Xenofon, Sieper, Joachim, Deodhar, Atul, Inman, Robert D, Kameda, Hideto, Zeng, Xiaofeng, Sui, Yunxia, Bu, Xianwei, Pangan, Aileen L, Wung, Peter, Song, In-Ho
Publicado 2022

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

por van der Heijde, Désirée, Deodhar, Atul, Maksymowych, Walter P, Sieper, Joachim, Van den Bosch, Filip, Kim, Tae-Hwan, Kishimoto, Mitsumasa, Östör, Andrew J, Combe, Bernard, Sui, Yunxia, Duan, Yuanyuan, Wung, Peter K, Song, In-Ho
Publicado 2022